Media & Resources

W. Ripley (“Rip”) Ballou, M.D., formerly of GSK, joined IAVI as ADVANCE Program Lead and Principal Investigator on April 1.

Mutual expertise drives innovations to address supply issues for vaccines for outbreak pathogens.

NEW YORK – January 29, 2020 – IAVI was deeply saddened to learn of the death of eminent scientist Maharaj Kishan Bhan, M.D., a longtime friend of IAVI. Dr. Bhan died on January 26, 2020, in New Delhi, India, at age 72. Dr. Bhan earned a medical degree from the Armed Forces Medical College in Pune,…

USAID-funded project propels HIV research through data science.

Partners collaborate in trial to evaluate whether vaccine candidate can prevent recurrence of TB disease.

Trial to evaluate safety, dosing, and immunogenicity of novel TB vaccine candidate.

Marburg virus has epidemic potential and is a high-priority agent that poses a national security threat.

Final results confirm the innovative TB candidate vaccine’s efficacy level and acceptable safety profile in three-year clinical trial conducted in sub-Saharan African regions.